On April 28, 2022 Lunit reported the presentation of 11 abstracts featuring its AI-biomarker platform at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting from June 3 to 7 (Press release, Lunit, APR 28, 2022, View Source [SID1234613187]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Since 2019, the company has presented groundbreaking findings based on its AI-powered tissue analysis platform, ‘Lunit SCOPE.’ This year’s ASCO (Free ASCO Whitepaper) Meeting will showcase the largest number of studies by Lunit, including seven poster presentations and four online publications.
One of Lunit’s presentations will focus on the use of AI technology to define tumor immune phenotypes. Findings from the study validate the effectiveness of Lunit SCOPE IO—Lunit’s AI biomarker—in predicting clinical outcomes of immunotherapy across more than 16 different cancer types.
Lunit’s other major study assesses the practical efficacy of Lunit SCOPE PD-L1, an AI-powered PD-L1 tumor proportion score (TPS) analyzer, which recently has received a CE mark.
In addition, Lunit will also present clinical findings that demonstrate the accuracy of its AI imaging solution in detecting high-risk breast cancer patients.
The company’s four abstracts due to be published online include a joint study to evaluate the performance of ‘Lunit SCOPE HER2’ in reducing interobserver variation among pathologists, as well as an examination of the landscape of tumor-infiltrating lymphocytes (TIL) in neuroendocrine tumors, a rare form of cancer, by using Lunit SCOPE IO.
"Through several studies, Lunit has demonstrated the credibility of Lunit SCOPE IO as a practical biomarker to predict cancer patients’ response to immunotherapy," said Chan-Young Ock, Chief Medical Officer at Lunit. "This study validates the efficacy of our AI biomarker as we continue to expand the range of our research across all cancer types originating from the epithelium."